Axogen appoints John H. Johnson to board, effective July 19, 2021

Axogen, Inc.

Board increased from eight to nine members; Johnson appointed effective July 19, 2021.
Johnson is CEO of Strongbridge Biopharma with 30+ years of biopharma experience.
He will serve on the Governance, Nominating and Sustainability Committee and Science and Technology Committee.
Standard director compensation: quarterly cash retainers ($10K board, $1.25K per committee) and stock option grants.
Johnson previously held senior roles at Eli Lilly, J&J, ImClone, and Dendreon.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Johnson

Director

AXGN · Axogen, Inc.

Effective: 2021-07-19
Filed: July 19, 2021, 7:59 PM ET

On July 16, 2021, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from eight to nine members, and appointed John Johnson as a new director, effective July 19, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Johnson was appointed as Director at Axogen, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 16, 2021, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from eight to nine members, and appointed John Johnson as a new director, effective July 19, 2021.

View on SEC.gov

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-21-000130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.